aod9604 vs retatrutide + AOD-9604 Blend | Research Grade AOD 9604 and retatrutide: evidence,

A simple weekly log works

However, insurance coverage can be trickier since its specifically for weight loss rather than diabetes management

A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026

Ethics declarations Conflict of interest Dina Halegoua-DeMarzio: Consultant- Pfizer

Contact Dr

One concern about GLP-1 medicines had been whether they were associated with an increase in risk of suicide or suicidal thoughts, prompting European regulators to open an investigation into the issue in 2023